BiTE therapy is under a bigger umbrella of the emerging trend of immunotherapy in cancer treatment. Pippas told the Ledger-Enquirer that Piedmont’s staff is preparing to fully incorporate these ...

A novel immunotherapy with extended serum half-life in a prodrug delivery format holds promise for overcoming the limitations of current BiTE therapies to treat a broad range of malignancies.

Doctors diagnosed Ellington with stage 4 small cell lung cancer in 2023. Her initial prognosis was a life expectancy of two to three months after chemo, and immunotherapy was unsuccessful in targeting ...